CASP5 Antibody (Center)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, FC, IHC-P, E |
---|---|
Primary Accession | P51878 |
Other Accession | NP_001129582.1, NP_001129584.1 |
Reactivity | Human |
Host | Rabbit |
Clonality | Polyclonal |
Isotype | Rabbit IgG |
Calculated MW | 49736 Da |
Antigen Region | 162-191 aa |
Gene ID | 838 |
---|---|
Other Names | Caspase-5, CASP-5, ICE(rel)-III, Protease ICH-3, Protease TY, Caspase-5 subunit p20, Caspase-5 subunit p10, CASP5, ICH3 |
Target/Specificity | This CASP5 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 162-191 amino acids from the Central region of human CASP5. |
Dilution | WB~~1:1000 IHC-P~~1:50~100 FC~~1:10~50 |
Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
Precautions | CASP5 Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | CASP5 {ECO:0000303|PubMed:16893518, ECO:0000312|HGNC:HGNC:1506} |
---|---|
Function | Thiol protease that acts as a mediator of programmed cell death (PubMed:29898893, PubMed:28314590). Initiates pyroptosis, a programmed lytic cell death pathway through cleavage of Gasdermin-D (GSDMD): cleavage releases the N-terminal gasdermin moiety (Gasdermin- D, N-terminal) that binds to membranes and forms pores, triggering pyroptosis (PubMed:29898893). Also mediates cleavage and maturation of IL18 (PubMed:37993714). Cleavage of GSDMD and IL18 is not strictly dependent on the consensus cleavage site but depends on an exosite interface on CASP4 (PubMed:37993714). During non-canonical inflammasome activation, cuts CGAS and may play a role in the regulation of antiviral innate immune activation (PubMed:28314590). |
Tissue Location | Expressed in barely detectable amounts in most tissues except brain, highest levels being found in lung, liver and skeletal muscle. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene encodes a member of the cysteine-aspartic acid protease (caspase) family. Sequential activation of caspases plays a central role in the execution-phase of cell apoptosis. Caspases exist as inactive proenzymes which undergo proteolytic processing at conserved aspartic residues to produce two subunits, large and small, that dimerize to form the active enzyme. Overexpression of the active form of this enzyme induces apoptosis in fibroblasts. Max, a central component of the Myc/Max/Mad transcription regulation network important for cell growth, differentiation, and apoptosis, is cleaved by this protein; this process requires Fas-mediated dephosphorylation of Max. The expression of this gene is regulated by interferon-gamma and lipopolysaccharide. Alternatively spliced transcript variants have been identified for this gene.
References
Ulybina, Y.M., et al. Exp. Gerontol. 45(9):726-729(2010)
Notaridou, M., et al. Int. J. Cancer (2010) In press :
Kim, M.S., et al. APMIS 118(4):308-312(2010)
Liang, X.S., et al. Br. J. Haematol. 146(4):418-423(2009)
Eckhart, L., et al. Biochem. Biophys. Res. Commun. 348(2):682-688(2006)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.